Cannabidiol as a Potential Treatment for Anxiety Disorders
Today, anxiety disorders are the most common of mental disorders and affect nearly 30% of adults at some point in their lives.
Anxiety statistics worldwide show that anxiety disorders are common across the globe. According to the World Health Organization, 3.6 percent — or about 264 million individuals worldwide — have an anxiety disorder. Additionally, 4.6 percent of females and 2.6 percent of males globally are affected by anxiety.
The share of the population with depression ranges mostly between 2% and 6% around the world today. Globally, older individuals (in the 70 years and older age bracket) have a higher risk of depression relative to other age groups.
Anxiety disorders arise in a number of forms including phobic, social, obsessive-compulsive (OCD), post-traumatic disorder (PTSD), or generalized anxiety disorders.
The symptoms and diagnostic criteria for each subset of anxiety disorders are unique. However, collectively the WHO’s International Classification of Diseases (ICD-10) note frequent symptoms of:
“(a) apprehension (worries about future misfortunes, feeling “on edge”, difficulty in concentrating, etc.);
(b) motor tension (restless fidgeting, tension headaches, trembling, inability to relax);
(c) autonomic overactivity (lightheadedness, sweating, tachycardia or tachypnoea, epigastric discomfort, dizziness, dry mouth, etc.).
In addition to the fact that anxiety disorder is a massive disease, it should be noted that, as a rule, it is treated with chemical medication. Because of the use of antidepressants and tranquilizers, most patients cannot do without them.
Here i will share the link to the article where you can find clinical studies on how CBD can help with anxiety disorders.
Clinical studies prove once again that people can live without pills and can live very fulfilling lives.
Overall, existing preclinical evidence strongly supports the potential of CBD as a treatment for anxiety disorders. CBD exhibits a broad range of actions, relevant to multiple symptom domains, including anxiolytic, panicolytic, and anticompulsive actions, as well as a decrease in autonomic arousal, a decrease in conditioned fear expression, enhancement of fear extinction, reconsolidation blockade, and prevention of the long-term anxiogenic effects of stress.